Karthikeyan Murugesan

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

Mark Yarchoan, Lee A. Albacker, Alexander C. Hopkins et al. · JCI Insight · 2019 · 538 citations · Full text

Medicine, Cancer Biology, Oncology +17

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo V. Negrão, Ferdinandos Skoulidis, Meagan Montesion et al. · Journal for ImmunoTherapy of Cancer · 2021 · 292 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Meagan Montesion, Karthikeyan Murugesan, Dexter X. Jin et al. · Cancer Discovery · 2020 · 248 citations · Full text

Medicine, Immunology, Oncology +17

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma

Gajanan Kendre, Karthikeyan Murugesan, Tilman Brummer et al. · Journal of Hepatology · 2022 · 162 citations · Full text

Medicine, Genetics, Oncology +17

Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).

Milind Javle, Karthikeyan Murugesan, Rachna T. Shroff et al. · Journal of Clinical Oncology · 2019 · 62 citations

Medicine, Genetics, Oncology +17